Immunization Strategies for the Immunocompromised Host: The Need for Immunoadjuvants
Authors: Patricia L. Hibberd
Journal: Annals of Internal Medicine (1989)

Editorials15 June 1989Immunization Strategies for the Immunocompromised Host: The Need for ImmunoadjuvantsPatricia L. Hibberd, MD, PhD, Robert H. Rubin, MDPatricia L. Hibberd, MD, PhDSearch for more papers by this author, Robert H. Rubin, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-110-12-955 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe publication of the second edition of the American College of Physicians'Guide for Adult Immunization( 1 ) will be an important event. First, it will be a tangible expression of the College's continuing commitment to preventive medicine in general and adult immunization in particular. Second, theGuidewill be a practical compendium of information for implementing an effective immunization strategy both for individual patients with special needs and for entire population groups. Finally, it 'will call the attention of the biomedical community—from the basic scientist to the clinician and public health planner—to important deficiencies in our present immunization...References1. Guide for Adult Immunization. 2d ed. Philadelphia: American College of Physicians; 1989 [In press]. Google Scholar2. GrossGouldBrown PLA. Effect of cancer chemotherapy on the immune response to influenza virus vaccine: review of published studies. Rev Inf Dis. 1985;7:613-8. CrossrefMedlineGoogle Scholar3. JacobsonJaffersDienstage IGJ. Immunogenicity of hepatitis B vaccine in renal transplant recipients. Transplantation. 1985;39:393-5. CrossrefMedlineGoogle Scholar4. DesmyterColaertDe Groote JJG. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Lancet. 1983;2:1323-7. CrossrefMedlineGoogle Scholar5. CrosnierJungersCourouce JPA. Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: 2. Haemodialysis patients. Lancet. 1981;1:797-800. CrossrefMedlineGoogle Scholar6. StevenAlterTaylor CHP. Hepatitis B vaccine in patients receiving hemodialysis. N Engl J Med. 1984;311:496-501. CrossrefMedlineGoogle Scholar7. LelieReesinkde Jong-van Manen PWS. Immune response to a heat-inactivated hepatitis B vaccine in patient undergoing hemodialysis—enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 µg. Arch Intern Med. 1985;145:305-9. CrossrefMedlineGoogle Scholar8. SteketeeZiarnikDavis RMJ. Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers, Wisconsin. Am J Epidemiol. 1988;127:772-82. CrossrefMedlineGoogle Scholar9. SeaworthDruckerStarlingDruckerStevensHamilton BJJRCJ. Hepatitis B vaccine in patients with chronic renal failure before dialysis. J Infect Dis. 1988;157:332-7. CrossrefMedlineGoogle Scholar10. FauciRosenbergSherwin ASS. Immunomodulators in clinical medicine. Ann Intern Med. 1987;106:421-33. LinkGoogle Scholar11. GrobJoller-JemelkaBinswangerZarubeDescoeudresFernex PHUKCM. Interferon as an adjuvant for hepatitis B vaccination in non- and low-responder populations. Eur J Clin Microbiol. 1984;3:195-8. CrossrefMedlineGoogle Scholar12. ProfetaGuidiMeroni MGP. Influenza vaccinations with adjuvant RU41740 in the elderly [Letter]. Lancet. 1987;1:973. CrossrefMedlineGoogle Scholar13. MeuerDumannMeyer zum BuschenfeldeKohler SHKH. Low dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet. 1989;1:15-7. CrossrefMedlineGoogle Scholar14. MeuerHauerKurzMeyer zum BushenfeldeKohler SMPKH. Selective blockade of the antigen-receptor mediated pathway of T cell activation in patients with impaired primary immune responses. J Clin Invest. 1987;80:743-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Massachusetts General Hospital Boston, Massachusetts PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByVaccine Adjuvants: The Current Necessity of LifeClinical ImmunologyVaccinations for Adult Solid-Organ Transplant Recipients: Current Recommendations and ProtocolsFuture challenges in analysis and treatment of human immune senescenceProphylactic Measures in the Solid‐Organ Recipient before TransplantationVACCINATION OF THE IMMUNOSUPPRESSED ADULT PATIENT WITH RHEUMATOLOGIC DISEASEImmunogenicity of Hepatitis A Vaccine in Decompensated Liver DiseaseHEPATITIS VACCINESImmunologic Adjuvants for Modern Vaccine FormulationsHEPATITIS VACCINESThe role of adjuvants in retroviral vaccinesClinical immunology of agingImpfungen bei sekundären Immundefekten — Indikationen, Impferfolge und KomplikationenFreund's complete adjuvant: an effective but disagreeable formulaThe child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategiesInfluence of Various Adjuvants on the Synthesis of Specific Antibodies of Chicken, Sheep and Rabbit Following Immunization with an Hapten*Approach to Immunization in the Immunosuppressed HostViral Infections in Dialysis Patients Part B: Dialysis Associated Hepatitis 15 June 1989Volume 110, Issue 12Page: 955-956KeywordsInfectious diseasesPrevention, policy, and public healthPreventive medicineScientists Issue Published: 15 June 1989 PDF DownloadLoading ...